10.1016/0304-3940(91)90422-P 295 TohgiH.AbeT.SahekiM.HamatoF.SasakiK.TakahashiS
Consistency and total plan quality matter more than pushing doses or stacking too many products
As body fat decreases, estrogen levels may shift (less aromatase activity), and HRT dosing may need adjustment
Published sensitization studies report rates below 1% in patch testing panels, and no carcinogenic or reproductive toxicity signals have emerged in long-term surveillance data
The marked positive trend reversal in P3 coincides with the publication of landmark GLP-1 Phase 3 trials, supporting the evidence that GLP-1-based therapies are key drivers of clinical research into weight loss in obese diabetic and non-diabetic populations, as well as their complications and comorbidities
Anxiety about whether the new medication will work, frustration during retitration periods when appetite returns, and the cognitive load of tracking two different dosing protocols all take a psychological toll